Pharmacogenomic effects on therapy for acute lymphoblastic leukemia in children

Pharmacogenomics Journal

Volumn 3, Issue 3, 2003, Pages 128-135

  Wall, A M ^a   Rubnitz, Jeffrey E ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMONAFIDE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; FOLIC ACID ANTAGONIST; FOLYLPOLYGLUTAMATE SYNTHASE; GAMMA GLUTAMYL HYDROLASE; GLUCOCORTICOID RECEPTOR; GYRASE INHIBITOR; MERCAPTOPURINE; METHOTREXATE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; MULTIDRUG RESISTANCE PROTEIN 2; TENIPOSIDE; TIOGUANINE; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHILD; CYTOTOXICITY; DRUG DNA INTERACTION; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; EXON; FIBROSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIVER TOXICITY; MISSENSE MUTATION; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHILD; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; PHARMACOGENETICS;

VINCA;

EID: 0038495592     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500174     Document Type: Article

References (60)

1. Pui C-H, Evans WE. N Engl J Med 1998; 339: 605-615.
2. Aarbakke J et al. Trends Pharmacol Sci 1997; 18: 3-7.
3. Elion GB. Science 1989; 244: 41-47.
4. Krynetski EY, Evans WE. Am J Hum Genet 1998; 63: 11-16.
5. McLeod H et al. Leukemia 2000; 14: 567-572.
6. Relling M et al. J Natl Can Inst 1999; 91: 2001-2008.
7. Lennard L. Ther Drug Monit 1998; 20: 527-531.
8. Evans WE et al. J Pediatr 1991; 119: 985-989.
9. Relling MV et al. Blood 1999; 93: 2817-2823.
10. Lennard L et al. Lancet 1990; 336: 225-229.
11. Bo J et al. Cancer 1999; 86: 1080-1086.
12. Relling MV et al. Leukemia 1998; 12: 346-352.
13. Relling MV et al. Lancet 1999; 354: 34-39.
14. Christophidis N et al. Cancer Chemother Pharmacol 1981; 6: 59-64.
15. Fabre G et al. Cancer Res 1983; 43: 4648-4652.
16. Masuda M et al. Cancer Res 1997; 57: 3506-3510.
17. Masson E et al. J Clin Invest 1996; 97: 73-80.
18. Westerhof GR et al. Cancer Res 1995; 55: 3795-3802.
19. Kobayashi H et al. Cancer Lett 1998; 124: 135-142.
20. Jansen G et al. J Biol Chem 1998; 273: 30189-30198.
21. Gong M et al. Blood 1997; 89: 2494-2499.
22. Brigle KE et al. Biochim Biophys Acta 1997; 1353: 191-198.
23. Gifford A et al. Proc Am Assoc Cancer Res 2000; 41: 758.
24. Belkov VM et al. Blood 1999; 93: 1643-1650.
25. Rots MG et al. Blood 1999; 93: 1677-1683.
26. Krajinovic M et al. Lancet 2002; 359: 1033-1034.
27. Molloy AM et al. Lancet 1997; 349: 1591-1593.
28. van der Put NM et al. Am J Hum Genet 1998; 62: 1044-1051.
29. Ulrich CM et al. Blood 2001; 98: 231-234.
30. Smets L et al. Leukemia Res 1985; 9: 199-207.
31. Abel S et al. J Steroid Biochem Mol Biol 1993; 45: 445-453.
32. Sata F et al. Clin Pharmacol Ther 2000; 67: 48-56.
33. Kleinbloesem CH et al. Biochem Pharmacol 1984; 33: 3721-3724.
34. Horsmans Y et al. Liver 1992; 12: 344-350.
35. Westlind A et al. Biochem Biophys Res Commun 1999; 259: 201-205.
36. Infante-Rivard C et al. Epidemiology 2002; 13: 277-281.
37. Schuetz E et al. Mol Pharmacol 1996; 49: 311-318.
38. Masuyama H et al. Mol Endocrinol 2000; 14: 421-428.
39. Relling M et al. Lancet 2000; 356: 285-290.
40. Baker D et al. J Clin Oncol 1992; 10: 311-315.
41. Kuehl P et al. Nat Genet 2001; 27: 383-391.
42. Huizenga N et al. J Clin Endo Metab 1998; 83: 144-151.
43. Chang TK et al. Cancer Res 1993; 53: 5629-5637.
44. Sullivan-Klose TH et al. Pharmacogenetics 1996; 6: 341-349.
45. Wrighton SA et al. J Clin Invest 1987; 80: 1017-1022.
46. Thum T, Borlak J. Lancet 2000; 355: 979-983.
47. Wong R-H et al. Mutat Res 1998; 420: 99-107.
48. Bunting KD, Townsend AJ. J Biol Chem 1996; 271: 11891-11896.
49. Raftogianis R et al. Biochem Biophys Res Commun 1997; 239: 298-304.
50. Hall A et al. Cancer Res 1994; 54: 5251-5254.
51. Tiirikainen MI et al. Leukemia 1994; 8: 978-984.
52. Dirven H et al. Cancer Res 1994; 54: 6215-6220.
53. Board P et al. Pharm Therap 1990; 48: 357-369.
54. Relling M et al. Mol Pharmacol 1994; 45: 352-358.
55. Mick R, Ratain MJ. J Natl Cancer Inst 1991; 83: 1560-1564.
56. Nebert D et al. DNA Cell Biol 1996; 15: 273-280.
57. Zhou-Pan X et al. Cancer Res 1993; 53: 5121-5126.
58. Kuwano M et al. Anticancer Drug Des 1999; 14: 123-131.
59. Licata S et al. Chem Res Toxicol 2000; 13: 414-420.
60. Marbeuf-Geuye C et al. Biochim Biophys Acta 1999; 1450: 374-384.